The Editor's Roundtable: The JUPITER Trial-Initial Results and Clinical Implications

American Journal of Cardiology

Volumn 103, Issue 10, 2009, Pages 1417-1425

  Ridker, Paul M ^a   Friedewald, Vincent E ^b   Davidson, Michael H ^c   Willerson, James T ^d   Roberts, William C ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d TEXAS HEART INSTITUTE   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; HEART INFARCTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLAMMATION; PRIMARY PREVENTION; PRIORITY JOURNAL;

EID: 65149100297     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.02.023     Document Type: Note

References (11)

1. Ridker P.M., Danielson E., Fonseca F.A.H., Genest J., Gotto Jr. A.M., Kastelein J.J.P., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
2. Ridker P.M., Rifai N., Pfeffer M.A., Downs J.R., Weis S.E., Miles J.S., Gotto A.M., and Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 344 (2001) 1959-1965
3. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., and Gotto Jr. A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
4. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J., and West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
5. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., and Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
6. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E., and Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98 (1998) 839-844
7. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., Orazem J., Magorien R.D., O'Shaughnessy C., Ganz P., and Reversal of Atherosclerosis with Aggressive Lipid lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
8. Morrow D.A., de Lemos J.A., Sabatine M.S., Wiviott S.D., Blazing M.A., Shui A., Rifai N., Califf R.M., and Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial. Circulation 114 (2006) 281-288
9. Ridker P.M., Morrow D.A., Rose L.M., Rifai N., Cannon C.P., and Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 45 (2005) 1644-1648
10. Arima H., Kubo M., Yonemoto K., Doi Y., Ninomiya T., Tanizaki Y., Hata J., Matsumura K., Iida M., and Kiyohara Y. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler Thromb Vasc Biol 28 (2008) 1385-1391
11. Kastelein J.J.P., Akdim F., Stroes E.S.G., Zwinderman A.H., Bots M.L., Stalenhoef A.F.H., Visseren F.L.J., Sijbrands E.J.G., Trip M.D., Stein E.A., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443